Life sciences venture capital firm 5AM Ventures closed its latest fund, at $285m.
According to a regulatory form filed with the SEC, 80 unnamed investors participated in the offering of 5AM Ventures V, L.P..
The document lists Managing Partners Kush M Parmar, MD, PhD, Scott M. Rocklage, PhD, and Andrew J. Schwab as people related to the raise.
Founded in 2002, 5AM Ventures actively invests in life science companies. With $970m under management, the firm has invested in over 55 early-stage companies and with realizations including DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics, Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia (acquired by Roche), Novira (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa.
Menlo Park, CA and Boston, MA-based 5AM recently launched 4:59 Initiative, an internal incubation program which aims to create and builds therapeutics companies based on innovative technologies. The program is led by CEO Louis A. Tartaglia, Ph.D.